Study wrapper · #775
Semaglutide and Risk of Adult-Onset Seizure: A Target Trial Emulation.
Editor's note
Using a research database, investigators emulated a target trial comparing semaglutide against SGLT2 inhibitors and other glucose-lowering drugs for the risk of adult-onset seizure in type 2 diabetes. Researchers reported semaglutide initiation was associated with lower seizure risk (weighted HR 0.44 vs other GLDs; 0.48 vs SGLT2i), with 4-year risk differences around 1.5-1.8% and NNT values (number needed for one to benefit) of 70 and 131; mediation through HbA1c and BMI was minimal. This is an observational emulation, graded Class II, and the authors are candid about low event counts, short follow-up and residual confounding, any of which could move the estimate. Read it as a hypothesis-generating association rather than proof of a neuroprotective effect. It is an intriguing addition to the pleiotropic-effects literature, best confirmed by prospective study.
Plain-language abstract
Researchers used a large health database to mimic a clinical trial, comparing adults with type 2 diabetes who started semaglutide against those who started other diabetes drugs, to see who was later diagnosed with a first adult seizure. People on semaglutide had a lower rate of new seizures, roughly half the risk of the comparison groups, and this did not seem to be explained by changes in blood sugar or weight. Because this is built from real-world records rather than a true randomised trial, other differences between the groups could partly explain the result. The number of seizure cases was small and follow-up was fairly short, so the authors call the evidence suggestive rather than conclusive. Confirming it would require a study that follows people forward over time.